CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...
Phase 4
San Francisco, California, United States and 29 other locations
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...
Phase 2
Fremont, California, United States of America and 35 other locations
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...
Phase 3
Fremont, California, United States of America and 36 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
San Francisco, California, United States and 179 other locations
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Phase 2
Fremont, California, United States and 79 other locations
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...
Phase 2
Lafayette, California, United States of America and 71 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Palo Alto, California, United States and 83 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Fremont, California, United States and 101 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
San Francisco, California, United States and 234 other locations
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Phase 1
Burlingame, California, United States
Clinical trials
Research sites
Resources
Legal